Panbela Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 25.26 million compared to USD 34.93 million a year ago. Basic loss per share from continuing operations was USD 316.52.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | -6.96% | +4.77% | -97.81% |
05-17 | North American Morning Briefing : The "Everything -2- | DJ |
05-15 | Transcript : Panbela Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.81% | 2.09M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- SNBP Stock
- News Panbela Therapeutics, Inc.
- Panbela Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023